Divi's Lab.

Which are the latest news on Divi's Lab.?

Why is Divis Laboratories Ltd falling/rising?

As of 30-Jul, Divis Laboratories Ltd's stock price is rising, currently at 7,840.50, reflecting a 0.6% increase. The stock has shown strong performance with significant gains over various periods, driven by solid fundamentals and increased investor confidence.

As of 30-Jul, Divis Laboratories Ltd's stock price is rising, currently at 7,840.50, with a change of 46.5 (0.6%) upwards. The stock has shown strong performance over various periods, including a 7.37% increase over the past week and a remarkable 19.20% rise over the last month. Year-to-date, the stock has gained 22.61%, significantly outperforming the Sensex, which has declined by 8.56% during the same period.<BR><BR>Today's performance is particularly noteworthy as the stock hit a new 52-week and all-time high of Rs. 7937. It has outperformed its sector by 0.91% today and has been on a consecutive gain streak for the last four days, accumulating an 8.19% return in that timeframe. Additionally, Divis Laboratories is trading above its moving averages across various time frames, indicating a strong upward trend.<BR><BR>Investor participation has also increased, with a delivery volume of 7.09 lacs on July 29, which is up by 223.2% compared to the five-day average. This rise in trading activity suggests growing confidence among investors. The company's solid fundamentals, including a high return on equity (ROE) of 16.32% and being net-debt free, further bolster its attractiveness. Moreover, the company has consistently reported positive results over the last seven quarters, with record net sales and operating profits.<BR><BR>Overall, the combination of strong recent performance, increased investor participation, and solid financial fundamentals contributes to the rising stock price of Divis Laboratories Ltd.

Should I buy, sell or hold Divis Laboratories Ltd?

How big is Divi's Lab.?

As of 10th June, Divis Laboratories Ltd has a market capitalization of 179,839.00 Cr, with recent net sales of 10,560.00 Cr and a net profit of 2,568.00 Cr.

As of 10th June, Divis Laboratories Ltd has a market capitalization of 179,839.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Divis Laboratories Ltd reported Net Sales of 10,560.00 Cr and a Net Profit of 2,568.00 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 14,969.00 Cr and Total Assets of 16,921.00 Cr.

Who are in the management team of Divi's Lab.?

The management team of Divi's Lab includes key members such as Murali K Divi (Chairman & Managing Director), Kiran S Divi (CEO), and several independent directors, overseeing the company's operations and strategic direction.

The management team of Divi's Lab includes the following key members:<BR><BR>1. **Murali K Divi** - Chairman & Managing Director<BR>2. **N V Ramana** - Executive Director<BR>3. **Madhusudana Rao Divi** - Whole Time Director (Projects)<BR>4. **Kiran S Divi** - Whole Time Director & CEO<BR>5. **Nilima Motaparti** - Whole Time Director - Commercial<BR>6. **G Suresh Kumar** - Independent Director<BR>7. **Ranga Rao Ravipati** - Independent Director<BR>8. **K V K Seshavataram** - Independent Director<BR>9. **Ramesh B V Nimmagadda** - Chairman (Non-Executive) & Independent Director<BR>10. **S Ganapaty** - Independent Director<BR>11. **Sunaina Singh** - Independent Director<BR>12. **Kosaraju Veerayya Chowdary** - Independent Director<BR>13. **Satish Choudhury** - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

Who are the peers of the Divi's Lab.?

Divi's Lab. peers include Sun Pharma, Torrent Pharma, Cipla, Zydus Lifesciences, Dr Reddy's Labs, Lupin, Mankind Pharma, Aurobindo Pharma, Laurus Labs, and Biocon. In terms of returns, Torrent Pharma leads with 42.88% over one year, while Divi's Lab. has a return of -0.26%.

Peers: The peers of Divi's Lab. are Sun Pharma.Inds., Torrent Pharma, Cipla, Zydus Lifesci., Dr Reddy's Labs, Lupin, Mankind Pharma, Aurobindo Pharma, Laurus Labs, and Biocon.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Torrent Pharma, Zydus Lifesci., Dr Reddy's Labs, Lupin, Mankind Pharma, Laurus Labs, and the rest. Below average growth is noted at Divi's Lab., Cipla, Aurobindo Pharma, and Laurus Labs, while excellent growth is seen at Sun Pharma.Inds., Zydus Lifesci., Lupin, Mankind Pharma, and the rest. Excellent capital structure is found at Sun Pharma.Inds., Divi's Lab., Cipla, Zydus Lifesci., Dr Reddy's Labs, Aurobindo Pharma, and the rest, while average capital structure is noted at Aurobindo Pharma and Biocon.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Torrent Pharma at 42.88%, while the lowest is Cipla at -8.95%. Divi's Lab. has a 1-year return of -0.26%, which is better than Cipla but worse than all other peers. Additionally, the peers with negative six-month returns are Cipla and Dr Reddy's Labs.

What does Divi's Lab. do?

Divi's Laboratories Limited is a major pharmaceutical company specializing in the manufacture of Active Pharmaceutical Ingredients (APIs) and Nutraceuticals, with a market cap of INR 179,839 Cr and a net profit of 751 Cr as of March 2026. It is recognized as one of the largest API manufacturers globally.

Overview:<BR>Divi's Laboratories Limited is a leading pharmaceutical company engaged in the manufacture of Active Pharmaceutical Ingredients (APIs), Intermediates, and Nutraceuticals, operating within the Pharmaceuticals & Biotechnology industry and classified as a Large Cap company.<BR><BR>History:<BR>Divi's Laboratories was incorporated in an unspecified year and has established itself as one of the world's largest API manufacturers. The latest quarterly results reported are for March 2026, showing significant sales and profit figures.<BR><BR>Financial Snapshot:<BR>- Net Sales: 2,831 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 751 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 179,839 Cr (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 67.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.44%<BR>- Debt Equity: -0.20<BR>- Return on Equity: 15.65%<BR>- Price to Book: 10.70<BR><BR>Contact Details:<BR>Address: 1-72-23(P)/DIVIS/303 Divi Tower, Cyber Hills Gachibowli Hyderabad Telangana : 500032<BR>Tel: 91-40-23786300/23786352/400<BR>Email: mail@divislabs.com<BR>Website: http://www.divislaboratories.com

Are Divis Laboratories Ltd latest results good or bad?

Divi's Laboratories Ltd reported strong Q4 FY26 results with a net profit of ₹751 crores, a 28.82% increase quarter-on-quarter and 13.44% year-on-year, alongside net sales growth of 8.72%. However, the decline in operating margins to 32.99% raises some concerns, suggesting that while the results are generally positive, investors should be cautious about profitability pressures.

Divi's Laboratories Ltd has reported solid results for Q4 FY26, indicating a generally positive performance. The company achieved a net profit of ₹751 crores, which marks a significant 28.82% increase compared to the previous quarter and a 13.44% rise year-on-year. This is the highest quarterly profit the company has recorded, reflecting strong operational momentum.<BR><BR>Additionally, net sales reached ₹2,831 crores, up 8.72% from the previous quarter and showing a year-on-year growth of 9.52%. These figures suggest that the company is experiencing robust demand for its products, particularly in its core active pharmaceutical ingredient (API) business.<BR><BR>However, there are some concerns regarding operational efficiency, as the operating margin (excluding other income) declined to 32.99% from 34.27% year-on-year. This indicates some pressure on profitability despite the overall growth in net profit.<BR><BR>In summary, while Divi's Laboratories has demonstrated strong growth in profits and sales, the decline in operating margins raises some caution. Overall, the results can be viewed as good, but investors may want to consider the implications of the margin pressure alongside the company's premium valuation in the market.

When is the next results date for Divis Laboratories Ltd?

The next results date for Divis Laboratories Ltd is 23 May 2026.

The next results date for Divis Laboratories Ltd is scheduled for 23 May 2026.

Is Divi's Lab. technically bullish or bearish?

As of December 1, 2025, Divi's Lab shows a mildly bullish trend, supported by bullish weekly MACD and Bollinger Bands, despite mixed signals from monthly indicators.

As of 1 December 2025, the technical trend for Divi's Lab has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, supporting a positive outlook. Daily moving averages are bullish, reinforcing the mildly bullish stance. However, the KST shows a bullish weekly trend but is mildly bearish monthly, and Dow Theory indicates no clear trend on both weekly and monthly charts. Overall, the current technical stance is mildly bullish, driven by the weekly MACD and Bollinger Bands, despite some bearish signals on the monthly indicators.

How has been the historical performance of Divi's Lab.?

Divi's Lab has shown consistent growth in net sales and profitability, with net sales increasing from 4,946.26 Cr in Mar'19 to 9,360.00 Cr in Mar'25, and profit after tax rising to 2,191.00 Cr in Mar'25. The company's total assets also grew significantly, reflecting a strong financial performance overall.

Answer:<BR>The historical performance of Divi's Lab shows a consistent growth trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Divi's Lab has demonstrated a steady increase in net sales, rising from 4,946.26 Cr in Mar'19 to 9,360.00 Cr in Mar'25. The total operating income followed a similar trajectory, reaching 9,360.00 Cr in Mar'25, up from 7,767.00 Cr in Mar'23. Operating profit (PBDIT) also saw fluctuations, peaking at 3,995.81 Cr in Mar'22 before settling at 3,320.00 Cr in Mar'25. Profit before tax increased to 2,916.00 Cr in Mar'25 from 2,163.00 Cr in Mar'24, while profit after tax reached 2,191.00 Cr in Mar'25, up from 1,600.00 Cr in Mar'24. The company's total assets grew significantly from 8,531.32 Cr in Mar'20 to 16,921.00 Cr in Mar'25, reflecting a robust expansion. Total liabilities also increased, but at a slower pace, indicating a strengthening balance sheet. Cash flow from operating activities improved to 1,653.00 Cr in Mar'25, contributing to a net cash inflow of 50.00 Cr for the year. Overall, Divi's Lab has shown resilience and growth in its financial performance across multiple metrics.

Who are the top shareholders of the Divi's Lab.?

The top shareholders of Divi's Lab include promoter Nilima Prasad Divi with 20.34%, foreign institutional investors holding 18.01%, mutual funds at 12.83%, and the Life Insurance Corporation of India as the largest public shareholder with 5.63%. Individual investors own 7.17% of the shares.

The top shareholders of Divi's Lab include the promoters, who hold the majority of the shares. Notably, Nilima Prasad Divi is the promoter with the highest holding at 20.34%. In addition, foreign institutional investors (FIIs) hold 18.01% of the shares, while mutual funds collectively account for 12.83% through 39 schemes. The highest public shareholder is the Life Insurance Corporation of India, which holds 5.63%. Individual investors also have a stake, representing 7.17% of the total shares.

What is the bonus history of the Divi's Lab.?

Divi's Laboratories has a history of issuing bonus shares, with the most recent being a 1:1 bonus announced on September 23, 2015, and a prior 1:1 bonus on August 1, 2009. This reflects the company's consistent practice of rewarding shareholders.

Divi's Laboratories has a history of issuing bonuses. The most recent bonus was a 1:1 bonus issue, which was announced with an ex-date of September 23, 2015, and the record date was September 26, 2015. Prior to that, the company also issued a 1:1 bonus on August 1, 2009, with an ex-date of July 30, 2009. This indicates that Divi's Lab has a consistent practice of rewarding its shareholders through bonus shares.

Has Divi's Lab. declared dividend?

Divis Laboratories Ltd has declared a 1500% dividend, amounting to ₹30 per share, with an ex-date of August 2, 2024. The company has shown strong total returns over various periods, particularly with a 169.61% total return over the past five years.

Divis Laboratories Ltd has declared a 1500% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 1500%<BR>- Amount per share: 30<BR>- Ex-date: 02 Aug 24<BR><BR>Dividend Yield: 0.45%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 5.9%, the dividend return was 0%, resulting in a total return of 5.9%.<BR><BR>Over the past year, the price return was 45.73%, the dividend return was 0.67%, leading to a total return of 46.4%.<BR><BR>In the 2-year period, the price return was 84.08%, the dividend return was 1.67%, culminating in a total return of 85.75%.<BR><BR>For the 3-year period, the price return was 85.98%, the dividend return was 2.50%, resulting in a total return of 88.48%.<BR><BR>In the last 4 years, the price return was 52.87%, the dividend return was 2.55%, leading to a total return of 55.42%.<BR><BR>Over the past 5 years, the price return was 164.6%, the dividend return was 5.01%, resulting in a total return of 169.61%.<BR><BR>Overall, Divis Laboratories Ltd has declared a significant dividend, and the total returns over various periods indicate strong performance, particularly in the long term, with substantial price appreciation and increasing dividend contributions.